| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Bone microarchitecture and estimated strength of primary osteoporosis patients treated with anti-resorptive (MIN), anabolic agents (dTPTD) were compared with non-treated historical control by using CT data of 3rd lumber spine. Both anti-resorptive and anabolic agents increased BMD, positively altered trabecular microarchitecture, and improved estimated strength. However, trabecular connectivity could not be restored by anti-resorptive treatment. Effect of denosumab for rheumatoid arthritis patients was evaluated, and positive effect on BMD and microarchitecture compared with non-treated historical control were confirmed. On the other hand, relationship between response to RIS and baseline characteristics of the patients were explored. BMD increased in response to RIS even when the patients were old and initial BMD was low, but early initiation of treatment would be recommended for preventing fracture. Moreover, monitoring bone turnover markers was useful in predicting future BMD gain.
|
